Reduced gluten exposure symptoms in non-celiac gluten sensitivity
Multiple RCTs have demonstrated DPP-IV-containing enzyme blends (often called AN-PEP or Tolerase G) reduce circulating gluten peptide concentrations and reduce post-exposure GI symptoms in non-celiac gluten-sensitive individuals. A 2015 RCT (Salden et al.) showed AN-PEP supplementation reduced gluten breakdown time by ~50% in vitro models replicating gastric and small intestinal conditions. Important caveat: this is supportive only — strict gluten avoidance remains the standard for celiac disease.
Casein peptide breakdown for dairy sensitivity
DPP-IV breaks down casomorphin peptides from milk casein digestion. Casomorphins (especially β-casomorphin-7 from A1 dairy) have been associated with GI sensitivity and possibly behavioral effects in some sensitive populations. Combined enzyme blends with DPP-IV reduce post-dairy symptoms in casein-sensitive individuals beyond what lactase alone provides (lactase only addresses lactose, not casein peptides).
Cross-contamination protection (NOT replacement for gluten-free diet)
For non-celiac individuals on a gluten-free diet (autoimmune Hashimoto's, eczema, IBS-D, etc.) who experience occasional accidental gluten exposure (restaurant cross-contamination, hidden gluten), DPP-IV supplementation can reduce symptom severity. AN-PEP-specific studies show reduced systemic gluten peptide concentrations after exposure. Critical: this is NOT safe for celiac patients, who require absolute gluten avoidance to prevent intestinal damage.
Improved digestive comfort in mixed-food sensitivity
When included in broad enzyme blends, DPP-IV contributes to comprehensive protein digestion and reduces post-meal symptoms in individuals with multiple food sensitivities. Particularly valuable for those with leaky gut conditions where peptide-driven inflammation is a contributing factor.
Cleavage at proline-containing peptide bonds
DPP-IV specifically cleaves peptide bonds where proline (or alanine) is in the second position from the N-terminus (i.e., X-Pro or X-Ala dipeptides). Gluten and casein contain unusually high proline content (gluten ~15%, casein 11%), creating proline-rich peptides resistant to most other proteases. This is why these peptides survive normal digestion and can trigger immune reactions in sensitive individuals.
Tolerase G (AN-PEP) — the most-studied DPP-IV supplement
AN-PEP (Aspergillus niger prolyl endoprotease, branded as Tolerase G) is the most clinically-studied DPP-IV product. It has additional prolyl endoprotease activity that cleaves internal proline bonds in immunogenic gluten peptides, particularly the 33-mer alpha-gliadin peptide implicated in celiac disease pathology. Acid-stable and active in stomach (pH 2-5).
Acid stability for stomach activity
Effective DPP-IV products are stable at gastric pH 2-5 — meaning they begin breaking down problem peptides immediately upon ingestion, before they reach the small intestine where immune-reactive peptide absorption can occur. This is a key advantage over neutral-pH-only enzymes.
Studies evaluating AN-PEP enzyme efficacy in degrading gluten peptides under simulated gastric conditions and in human pilot studies measuring circulating gluten peptide levels after gluten challenge.
Healthy adults with confirmed non-celiac gluten sensitivity.
AN-PEP degraded gluten peptides ~50% faster than control. Reduced circulating immunogenic gluten peptides post-challenge. Did not eliminate gluten exposure but significantly reduced peptide load. Important: this study explicitly noted that AN-PEP is NOT recommended as substitute for gluten-free diet in celiac disease.
60-day randomized, double-blind, placebo-controlled trial of 5-enzyme blend (protease, lipase, amylase, cellulase, lactase, DPP-IV) in functional dyspepsia patients.
Adults with functional dyspepsia.
Significant reductions in GI symptoms (bloating, fullness, post-prandial distress) vs. placebo. While not isolating DPP-IV's specific contribution, this study supports clinical efficacy of multi-enzyme approaches that include DPP-IV.